Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak
Go back to Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak| Harmony Metals, Inc. Common (NASDAQ: HRMY) | Delayed: 42.03 +0.01 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.02 | 52 Week High | $1.35 | |||
| Open | $41.87 | 52 Week Low | $0.10 | |||
| Day High | $42.52 | P/E | N/A | |||
| Day Low | $41.20 | EPS | $0.00 | |||
| Volume | 143,125 | |||||
